Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel Group, Multicenter Study of Fluticasone Furoate/Vilanterol 200/25 mcg Inhalation Powder, Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, and Fluticasone Furoate 100 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents
Brief Summary: This is a Phase III, multicenter, randomized, double-blind, stratified, parallel-group study with three active comparators in subjects with moderate to severe persistent asthma. The study consists of a run-in period of 4 weeks, followed by a treatment period of 12 weeks, and a follow up contact period of one week. The total duration of the study is 17 weeks. 990 subjects will be randomized to one of three treatments (FF/VI Inhalation Powder 200/25 mcg once daily in the evening; FF/VI Inhalation Powder 100/25 mcg once daily in the evening; FF 100 Inhalation Powder once daily in the evening) for 12 weeks. In addition, all subjects will be supplied albuterol/salbutamol inhalation aerosol at Visit 1 to use as needed for acute asthma symptoms throughout the entire study. Subjects will attend four on-treatment visits at Weeks 2, 4, 8, and 12 (Visits 4 through 7).


Options:
A: Arm Label: Fluticasone furoate 50mcg; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate 50mcg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone furoate 50mcg; Assigned to Arm(s): Fluticasone furoate 50mcg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: FF/UMEC/VI (100/31.25/25) mcg closed triple therapy; Type: EXPERIMENTAL; Interventions: Drug: FF/UMEC/VI (100/31.25/25) mcg, Drug: FF/VI (100/25) mcg, Drug: Fluticasone/salmeterol (FSC), Drug: Albuterol/salbutamol, Device: ELLIPTA DPI, Device: DISKUS DPI, Device: METERED-DOSE INHALER (MDI) | Arm Label: FF/UMEC/VI (100/62.5/25) mcg closed triple therapy; Type: EXPERIMENTAL; Interventions: Drug: FF/UMEC/VI (100/62.5/25) mcg, Drug: FF/VI (100/25) mcg, Drug: Fluticasone/salmeterol (FSC), Drug: Albuterol/salbutamol, Device: ELLIPTA DPI, Device: DISKUS DPI, Device: METERED-DOSE INHALER (MDI) | Arm Label: FF/UMEC/VI (200/31.25/25) mcg closed triple therapy; Type: EXPERIMENTAL; Interventions: Drug: FF/UMEC/VI (200/31.25/25) mcg, Drug: FF/VI (100/25) mcg, Drug: Fluticasone/salmeterol (FSC), Drug: Albuterol/salbutamol, Device: ELLIPTA DPI, Device: DISKUS DPI, Device: METERED-DOSE INHALER (MDI) | Arm Label: FF/UMEC/VI (200/62.5/25) mcg closed triple therapy; Type: EXPERIMENTAL; Interventions: Drug: FF/UMEC/VI (200/62.5/25) mcg, Drug: FF/VI (100/25) mcg, Drug: Fluticasone/salmeterol (FSC), Drug: Albuterol/salbutamol, Device: ELLIPTA DPI, Device: DISKUS DPI, Device: METERED-DOSE INHALER (MDI) | Arm Label: FF/VI (100/25) mcg dual combination therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: FF/VI (100/25) mcg, Drug: Fluticasone/salmeterol (FSC), Drug: Albuterol/salbutamol, Device: ELLIPTA DPI, Device: DISKUS DPI, Device: METERED-DOSE INHALER (MDI) | Arm Label: FF/VI (200/25) mcg dual combination therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: FF/VI (100/25) mcg, Drug: FF/VI (200/25) mcg, Drug: Fluticasone/salmeterol (FSC), Drug: Albuterol/salbutamol, Device: ELLIPTA DPI, Device: DISKUS DPI, Device: METERED-DOSE INHALER (MDI) | Intervention Type: DRUG; Name: FF/UMEC/VI (100/31.25/25) mcg; Assigned to Arm(s): FF/UMEC/VI (100/31.25/25) mcg closed triple therapy | Intervention Type: DRUG; Name: FF/UMEC/VI (100/62.5/25) mcg; Assigned to Arm(s): FF/UMEC/VI (100/62.5/25) mcg closed triple therapy | Intervention Type: DRUG; Name: FF/UMEC/VI (200/31.25/25) mcg; Assigned to Arm(s): FF/UMEC/VI (200/31.25/25) mcg closed triple therapy | Intervention Type: DRUG; Name: FF/UMEC/VI (200/62.5/25) mcg; Assigned to Arm(s): FF/UMEC/VI (200/62.5/25) mcg closed triple therapy | Intervention Type: DRUG; Name: FF/VI (100/25) mcg; Assigned to Arm(s): FF/UMEC/VI (100/31.25/25) mcg closed triple therapy, FF/UMEC/VI (100/62.5/25) mcg closed triple therapy, FF/UMEC/VI (200/31.25/25) mcg closed triple therapy, FF/UMEC/VI (200/62.5/25) mcg closed triple therapy, FF/VI (100/25) mcg dual combination therapy, FF/VI (200/25) mcg dual combination therapy | Intervention Type: DRUG; Name: FF/VI (200/25) mcg; Assigned to Arm(s): FF/VI (200/25) mcg dual combination therapy | Intervention Type: DRUG; Name: Fluticasone/salmeterol (FSC); Assigned to Arm(s): FF/UMEC/VI (100/31.25/25) mcg closed triple therapy, FF/UMEC/VI (100/62.5/25) mcg closed triple therapy, FF/UMEC/VI (200/31.25/25) mcg closed triple therapy, FF/UMEC/VI (200/62.5/25) mcg closed triple therapy, FF/VI (100/25) mcg dual combination therapy, FF/VI (200/25) mcg dual combination therapy | Intervention Type: DRUG; Name: Albuterol/salbutamol; Assigned to Arm(s): FF/UMEC/VI (100/31.25/25) mcg closed triple therapy, FF/UMEC/VI (100/62.5/25) mcg closed triple therapy, FF/UMEC/VI (200/31.25/25) mcg closed triple therapy, FF/UMEC/VI (200/62.5/25) mcg closed triple therapy, FF/VI (100/25) mcg dual combination therapy, FF/VI (200/25) mcg dual combination therapy | Intervention Type: DEVICE; Name: ELLIPTA DPI; Assigned to Arm(s): FF/UMEC/VI (100/31.25/25) mcg closed triple therapy, FF/UMEC/VI (100/62.5/25) mcg closed triple therapy, FF/UMEC/VI (200/31.25/25) mcg closed triple therapy, FF/UMEC/VI (200/62.5/25) mcg closed triple therapy, FF/VI (100/25) mcg dual combination therapy, FF/VI (200/25) mcg dual combination therapy | Intervention Type: DEVICE; Name: DISKUS DPI; Assigned to Arm(s): FF/UMEC/VI (100/31.25/25) mcg closed triple therapy, FF/UMEC/VI (100/62.5/25) mcg closed triple therapy, FF/UMEC/VI (200/31.25/25) mcg closed triple therapy, FF/UMEC/VI (200/62.5/25) mcg closed triple therapy, FF/VI (100/25) mcg dual combination therapy, FF/VI (200/25) mcg dual combination therapy | Intervention Type: DEVICE; Name: METERED-DOSE INHALER (MDI); Assigned to Arm(s): FF/UMEC/VI (100/31.25/25) mcg closed triple therapy, FF/UMEC/VI (100/62.5/25) mcg closed triple therapy, FF/UMEC/VI (200/31.25/25) mcg closed triple therapy, FF/UMEC/VI (200/62.5/25) mcg closed triple therapy, FF/VI (100/25) mcg dual combination therapy, FF/VI (200/25) mcg dual combination therapy
C: Arm Label: Arm1: Fluticasone Furoate/ Vilanterol 200/25 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/ Vilanterol 200/25 mcg | Arm Label: Arm 2: Fluticasone Furoate/ Vilanterol 100/25 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/ Vilanterol 100/25 mcg | Arm Label: Arm 3: Fluticasone Furoate 100 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate 100 mcg | Intervention Type: DRUG; Name: Fluticasone Furoate/ Vilanterol 200/25 mcg; Assigned to Arm(s): Arm1: Fluticasone Furoate/ Vilanterol 200/25 mcg | Intervention Type: DRUG; Name: Fluticasone Furoate/ Vilanterol 100/25 mcg; Assigned to Arm(s): Arm 2: Fluticasone Furoate/ Vilanterol 100/25 mcg | Intervention Type: DRUG; Name: Fluticasone Furoate 100 mcg; Assigned to Arm(s): Arm 3: Fluticasone Furoate 100 mcg
D: Arm Label: QVM149 150/50/160 µg o.d.; Type: EXPERIMENTAL; Interventions: Drug: QVM149 150/50/160 | Arm Label: QVM149 150/50/80 µg o.d.; Type: EXPERIMENTAL; Interventions: Drug: QVM149 150/50/80 | Arm Label: QMF149 150/320 µg o.d.; Type: ACTIVE_COMPARATOR; Interventions: Drug: QMF149 150/320 | Arm Label: QMF149 150/160 µg o.d.; Type: ACTIVE_COMPARATOR; Interventions: Drug: QMF149 150/160 | Arm Label: Salmeterol/fluticasone 50/500 μg b.i.d.; Type: ACTIVE_COMPARATOR; Interventions: Drug: salmeterol/fluticasone | Intervention Type: DRUG; Name: QVM149 150/50/160; Assigned to Arm(s): QVM149 150/50/160 µg o.d. | Intervention Type: DRUG; Name: QVM149 150/50/80; Assigned to Arm(s): QVM149 150/50/80 µg o.d. | Intervention Type: DRUG; Name: QMF149 150/320; Assigned to Arm(s): QMF149 150/320 µg o.d. | Intervention Type: DRUG; Name: QMF149 150/160; Assigned to Arm(s): QMF149 150/160 µg o.d. | Intervention Type: DRUG; Name: salmeterol/fluticasone; Assigned to Arm(s): Salmeterol/fluticasone 50/500 μg b.i.d.

Answer: C